Clinical trials: Chronic Hepatitis
Hepatitis B, Chronic
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine
- Trial name
- DEFINE (NCT00410202)
- Testing
- Entecavir, Tenofovir, Adefovir
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 629 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)
In this study, participants with hepatitis C virus (HCV) genotype 1 (GT1) who failed prior direct-acting antiviral (DAA) therapy will receive Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) to evaluate sustained…
- Trial name
- NCT02105454
- Testing
- Grazoprevir (GZR), Elbasvir (EBR), Ribavirin (RBV)
- Volunteers
- 79 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects
GSK3389404 is being developed for the treatment of CHB virus infection. The development goal for GSK3389404 is the establishment of a finite duration treatment that results in sustained suppression of hepatitis B virus (HBV)…
- Trial name
- NCT03020745
- Testing
- GSK3389404
- Where
- 21 sites in China, Hong Kong and 4 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin in genotype 1 hepatitis C virus (HCV)-infected participants who relapsed after…
- Trial name
- NCT01290731
- Testing
- TMC435, Pegylated interferon (pegIFN alpha-2a), Ribavirin (RBV)
- Where
- 10 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
The purpose of this study is to provide confirmatory efficacy and safety data of TMC435 as part of a treatment regimen including peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) in patients with genotype 1 Hepatitis C virus…
- Trial name
- NCT01725529
- Testing
- TMC435, Peginterferon-alpha (PegIFNα-2a), Ribavirin (RBV)
- Where
- 21 sites in China, South Korea
- Volunteers
- 457 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C Virus
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to determine if concentration-controlled ribavirin dosing can achieve a targeted level of plasma exposures and if it appears safe and effective compared with standard weight-based ribavirin dosing.
- Trial name
- NCT01097395
- Testing
- ribavirin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Colorado, Denver
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
Several psychiatric adverse events (eg, depression, fatigue, psychoses, behavior troubles, anxiety, irritability, deteriorated concentration, and insomnia) that are likely to occur during the treatment course with PegIntron plus…
- Trial name
- NCT00723892
- Testing
- Peginterferon alfa-2b (PegIntron), Rebetol (Ribavirin), Psychotherapy support program
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)
This study will evaluate the technical feasibility of using fine needle aspiration (FNA) of liver tissue to obtain vaniprevir (MK-7009) liver pharmacokinetic (PK) data, working towards identifying a minimally invasive…
- Trial name
- NCT01678131
- Testing
- Vaniprevir 600 mg, Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV)…
- Trial name
- NCT04112303
- Testing
- SOF/VEL
- Where
- 22 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Gilead Sciences
Genotype 1 Hepatitis C Virus
Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with Genotype 1 HCV infection
- Trial name
- NCT02759861
- Testing
- harvoni
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Nebraska
Hepatitis B, Chronic
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV).
- Trial name
- NCT01095835
- Testing
- Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM)
- Where
- 22 sites in Italy
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection
- Trial name
- NCT00546715
- Testing
- Daclatasvir
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide analog [NA] and pegylated interferon…
- Trial name
- PENGUIN (NCT04667104)
- Testing
- JNJ-73763989, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Where
- 11 sites in Japan, New Zealand and 2 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis C
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02798315
- Volunteers
- 40 people
- Sponsor
- AbbVie
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01715415
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and antiviral activity of multiple, ascending doses of ABT-267 (also known as ombitasvir) administered as two-day monotherapy followed by ABT-267…
- Trial name
- NCT01563536
- Testing
- ABT-267, ABT-450, ABT-333
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
- Trial name
- ALLY 3 (NCT02032901)
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT01466192
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 108 people
- Sponsor
- Tanabe Pharma Corporation